Maze Therapeutics begins Phase 2 trial for kidney disease drug By Investing.com - Feb 07, 2025 SOUTH SAN FRANCISCO – Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical ...

Ghosts Australia will film in Perth, thanks to the Western Australian Production Attraction Incentive, and screen on both Paramount+ and Network 10 later in the year. Young lovebirds Kate and Sean are ...

Samsung opts for vibrant colors for the Galaxy S25 wallpapers collection. For Galaxy S25 and S25 Plus, the wallpaper collection dawns Blueblack, Coralred, Silver Shadow, Navy, Mint, and Icy Blue.

Tech stocks led the market on Wednesday as Netflix (NFLX) stock surged to a record, while President Donald Trump's boost to AI demand hopes outweighed fresh tariff worries. Meanwhile, the Dow ...

Nvidia (NASDAQ: NVDA) stock posted significant gains in Wednesday's trading following bullish artificial intelligence (AI) news. The company's share price closed out the day up 4.4% amid the ...

Shares of Grail, a medical technology company, jumped 20% Wednesday to lead Nasdaq 100 gainers. Grail spun off from Illumina last year, and is developing a number of early detection cancer ...

The Nasdaq 100 Index has nearly doubled since the start of 2023, adding $14 trillion in value in the process. Evercore ISI’s Rich Ross is prepared for that rally to continue, shrugging off fears ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: JPMorgan Chase & Co. JPM: This financial services giant has seen the Zacks Consensus Estimate for its current year earnings ...

Netflix (Nasdaq: NFLX) is one of the more notable gainers today. We hosted a live blog during their earnings yesterday, and it was full of enthusiasm. The headline is the company added nearly 19 ...